The buyback is proceeding as scheduled with no deviation from the announced plan. Monitor future 6-K filings for continued execution pace and any changes to the authorization.
Price Chart
Executive Summary
Novo Nordisk filed a routine 6-K disclosing weekly B-share repurchases under its existing DKK 15 billion buyback program. Since the last announcement on October 5, the company repurchased 1,245,000 B shares for approximately DKK 311.6 million. The program is on track, with total repurchases of DKK 10.56 billion since February 4, 2026, against the DKK 15 billion authorization. This is a routine capital allocation update with no material new information.
Key Facts
- Novo Nordisk repurchased 1,245,000 B shares from October 5-9, 2026, for a total transaction value of approximately DKK 311.6 million.
- Cumulative repurchases under the May 6, 2026 sub-program total 23,090,000 B shares for DKK 6.76 billion.
- Since February 4, 2026, the company has repurchased 37,849,179 B shares at an average price of DKK 278.97 per share, totaling DKK 10.56 billion.
- The overall buyback program authorizes up to DKK 15 billion over a 12-month period ending February 1, 2027.
- Novo Nordisk now holds 51,889,876 B shares as treasury shares, representing 1.2% of total share capital.
Financial Impact
Routine weekly buyback disclosure; no material financial impact beyond previously announced program.
Risk Factors
- No material risks identified; this is a routine disclosure of an ongoing buyback program.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006585 |
| Document: 0001171843-26-006585-index-headers.html | 0001171843-26-006585 |
| Document: 0001171843-26-006585-index.html | 0001171843-26-006585 |
| Document: 0001171843-26-006585.txt | 0001171843-26-006585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 2d ago | 6-K | $39.13 | awaiting T+20 | awaiting T+20 | $38.29 (−2.15%) |
Oct 26, 2026 3d ago | Court Ruling | $38.67 | awaiting T+20 | awaiting T+20 | $38.29 (−0.98%) |
Oct 19, 2026 9d ago | 6-K | $38.42 | awaiting T+20 | awaiting T+20 | $38.29 (−0.34%) |
Oct 13, 2026 16d ago | 6-K | $38.06 | awaiting T+20 | awaiting T+20 | $38.29 (+0.60%) |
Oct 6, 2026 22d ago | 6-K | $37.53 | awaiting T+20 | awaiting T+20 | $38.29 (+2.03%) |
Sep 28, 2026 4w ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $38.29 (−1.08%) |
Sep 23, 2026 5w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $38.29 (−0.85%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $38.29 (−3.79%) |
Sep 17, 2026 5w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $38.29 (−11.35%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $38.29 (−9.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers